

<sup>1</sup>For consistency this report follows the format used by the U.S. National Newborn Screening & Genetics Resource Center  
 A dot "●" indicates that screening for the condition is universally required by Law  
**A** = universally offered but not yet required, **B** = offered to select populations or by request, **C** = testing required or offered universally but not yet implemented, **D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law

Province/Territory (east to west/ west to east)	Core <sup>1</sup> Conditions:									Additional Conditions Included (universally offered unless otherwise indicated)
	Hearing	Endocrine		Hemoglobin (HB)			Other			
	HEAR	CH	CAH	S/S	S/C	S/A	BIO	GALT	CF	
Newfoundland & Labrador		A								Homocystinuria (one region); added MCAD and HCY in mid-2006
Prince Edward Island	A	A								Covered by NBS Lab in Nova Scotia
Nova Scotia	A	A								HB pilot under consideration; discussing CF; added LCHAD, MSUD & IVA April, 2006
New Brunswick	A	A								Plan to expand to 15 by end 2006; regional collaboration with Nova Scotia; maintain PKU in NB
Quebec	A	A								Second screen by urine collected by parent at newborn Day 21 – 90% participation: 12 conditions of amino, urea cycle & organic acids plus 11 transport disorders of amino acids (Fanconi syndrome, Cystinurias, Hartnup syndrome, Cystathioninemia, Prolidase deficiency, etc.)
Ontario	A	A	C	A	A	A	C	C	C <sup>1</sup>	C = to be universally offered by end 2006 C <sup>1</sup> = to be universally offered by end 2007
Manitoba	A	A	A				A	A		targeted screening for GA1 (Ojii-Crees), CPT1 (Hutterites) and Duchenne muscular dystrophy (males)
Saskatchewan	B	●	C				C	B		Plan to add Biotinidase (BIO) and Congenital Adrenal Hyperplasia (CAH) in 2006
Alberta	B	A	C				A		C	Pilot for universal hearing screening in 4 regions (Calgary, Chinook, Mistahia & Palliser); CF universal pilot since May, 2005 in Calgary region; C = 13 to be universally offered by April 2007
British Columbia	A	A						A		
Yukon	A	A						A		Covered by NBS lab in British Columbia
Northwest Territories - western	B	A					A			Covered by NBS lab in Alberta
Northwest Territories - eastern	A	A								Covered by NBS lab in Manitoba
Nunavut - western	A	A	A				A	A		Covered by NBS lab in Manitoba
Nunavut - eastern	A	A								Covered by NBS labs in Quebec; Second screen by urine sample at newborn Day 21 – 23 conditions

**Deficiency/Disorder Abbreviations and Names**

<b>BIO</b>	Biotinidase	<b>CF</b>	Cystic fibrosis	<b>GALT</b>	Transferase deficient galactosemia (Classical)	<b>HB S/C</b>	Sickle – C disease	<b>HEAR</b>	Hearing screening
<b>CAH</b>	Congenital adrenal hyperplasia	<b>CH</b>	Congenital hyperthyroidism	<b>HB S/S</b>	Sickle cell disease	<b>HB S/A</b>	S-βeta thalassemia		

**Other Disorders**

<b>5-OXO</b>	5-oxoprolinuria (pyroglutamic aciduria)	<b>G6PD</b>	Glucose 6 phosphate dehydrogenase	<b>NKH</b>	Nonketotic hyperglycinemia
<b>CPS</b>	Carbamoylphosphate synthetase	<b>HHH</b>	Hyperammonemia/ornithinemia/ citrullinemia (Ornithine transporter defect)	<b>OTC</b>	Ornithine transcarbamylse
<b>EMA</b>	Ethylmalonic encephalopathy	<b>HIV</b>	Human immunodeficiency virus	<b>TOXO</b>	Toxoplasmosis

A dot "●" indicates that screening for the condition is universally required by Law  
**A** = universally offered but not yet required, **B** = offered to select populations or by request, **C** = testing required or offered universally but not yet implemented, **D** = likely to be detected (and reported) as a by-product of MRM screening (MS/MS) targeted by Law

Province/Territory (east to west; west to east)	Core <sup>1</sup> Conditions: Metabolic																			
	Fatty Acid Disorders					Organic Acid Disorders									Amino Acid Disorders					
	CUD	LCHAD	MCAD	TFP	VLCAD	GA-I	HMG	IVA	3-MCC	Cbl-A,B	BKT	MUT	PROP	MCD	ASA	CIT	HCY	MSUD	PKU	TYR-I
Newfoundland & Labrador			A																A	A
Prince Edward Island	A	A	A	A	A	A		A										A	A	
Nova Scotia	A	A	A	A	A	A		A										A	A	
New Brunswick: C = universally offered by end 2006	C	C	C	C	C	C		C										C	A	
Quebec						A	A	A	A	A		A		A	A				A	A
Ontario	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A
Manitoba						B													A	
Saskatchewan	B	A	A	A	A	A	A	A	A	A	A	A	A	A	B	A	B	A	●	A
Alberta C = universally offered by April 2007	C	C	C	C	C	C	C	C		C			C		C	A	A	A	A	A
British Columbia			A																A	
Yukon			A																A	
Northwest Territories - western																			A	
Northwest Territories - eastern																			A	
Nunavut - western																			A	
Nunavut - eastern						A	A	A	A	A		A		A	A				A	A

<sup>1</sup>Terminology consistent with American College of Medical Genetics report - Newborn Screening: Toward a Uniform Screening Panel and System 2005, p. 63.

**Deficiency/Disorder Abbreviations and Names (optional nomenclature)**

<b>3-MCC</b>	3-Methylcrotonyl-CoA carboxylase	<b>CUD</b>	Carnitine uptake defect (Carnitine transport defect)	<b>LCHAD</b>	Long-chain hydroxyacyl-CoA dehydrogenase	<b>PKU</b>	Phenylketonuria/hyperphenylalaninemia
<b>ASA</b>	Argininosuccinate acidemia	<b>GA-1</b>	Glutaric acidemia type 1	<b>MCAD</b>	Medium-chain acyl-CoA dehydrogenase	<b>PROP</b>	Propionic acidemia (Propionyl-CoA carboxylase)
<b>BKT</b>	Beta ketothiolase (mitochondrial acetoacetyl-CoA thiolase ; short-chain ketoacyl thiolase; T2)	<b>HCY</b>	Homocystinuria (cystathionine beta synthase)	<b>MCD</b>	Multiple carboxylase (Holocarboxylase synthetase)	<b>TFP</b>	Trifunctional protein
<b>CBL A,B</b>	Methylmalonic acidemia (Vitamin B12 Disorders)	<b>HMG</b>	3-Hydroxy 3 - methylglutaric aciduria (3-Hydrox 3- methylglutaryl-CoA lyase )	<b>MSUD</b>	Maple syrup urine disease (branched-chain ketoacid dehydrogenase )	<b>TYR-1</b>	Tyrosinemia Type 1
<b>CIT I</b>	Citrullinemia type I (Argininosuccinate synthetase)	<b>IVA</b>	Isovaleric acidemia (Isovaleryl-CoA dehydrogenase )	<b>MUT</b>	Methylmalonic Acidemia (methylmalonyl-CoA mutase)	<b>VLCAD</b>	Very long-chain acyl-CoA dehydrogenase

